Beskrivelse
Krav
Fullmektig i Norge:
Fullmektig i EP:
Avsender
Statushistorie for 2025/01338
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
Under behandling | Mottatt |
Korrespondanse for 2025/01338
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende, AR661139494
Generell henvendelse Adresseendring fullmektig!!
|
2016.02.04, US 201662291202 P
2016.08.09, US 201615232647
2016.10.04, US 201615285264
2017.01.09, US 201762444036 P
- Riken Chemical Industrial Co Ltd: "JPS5944318 - English translation", , 12 March 1984 (1984-03-12), XP055749242, Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
US-A1- 2016 263 245 (B1)
ANDRZEJ ZALESKI ET AL: "Butyric acid in irritable bowel syndrome", GASTROENTEROLOGY REVIEW, vol. 6, 1 January 2013 (2013-01-01), pages 350-353, XP055426645, ISSN: 1895-5770, DOI: 10.5114/pg.2013.39917 (B1)
EP-A1- 0 839 528 (B1)
EP-A1- 2 740 475 (B1)
Edwin Moran: "Digestion and Absorption of Carbohydrates in Fowl and Events through Perinatal Development", , 4 December 1984 (1984-12-04), XP055749277, Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
H.H. Chauncey: "Comparative Enzyme Activity of Saliva From The Sheep, Hog, Dog, Rabbit, Rat and Human", , 1 January 1963 (1963-01-01), XP055749250, Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
JP-A- S5 944 318 (B1)
KRATSMAN NETA ET AL: "Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model", NEUROPHARMACOLOGY, vol. 102, 11 November 2015 (2015-11-11), pages 136-145, XP029372059, ISSN: 0028-3908, DOI: 10.1016/J.NEUROPHARM.2015.11.003 (B1)
Lafayette Mendel: "Is the saliva of the dog amylolytically active?", J. Biol. Chem, 19 March 1907 (1907-03-19), XP055749247, Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
MCMULLAN R K ET AL: "Topography of cyclodextrin inclusion complexes", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 31, no. 1, 1 November 1973 (1973-11-01), pages 37-46, XP026680204, ISSN: 0008-6215, DOI: 10.1016/S0008-6215(00)82315-0 [retrieved on 1973-11-01] (B1)
OWUMI ET AL.: 'Co-administration of N-acetylcysteine and Acetaminophen Efficiently Blocks Acetaminophen Toxicity' DRUG DEV RES vol. 76, no. 5, August 2015, pages 251 - 258, XP055406152 (B1)
ROBERT I. GELB ET AL: "Complexation of carboxylic acids and anions by alpha and beta cyclodextrins", JOURNAL OF INCLUSION PHENOMENA AND MOLECULAR RECOGNITION IN CHEMISTRY., vol. 7, no. 4, 1 August 1989 (1989-08-01), pages 465-476, XP055605132, NL ISSN: 0923-0750, DOI: 10.1007/BF01079783 (B1)
ROY ET AL.: 'Host-guest inclusion complexes of alpha and beta-cyclodextrins with alpha-amino acids' RSC ADVANCES vol. 4, September 2014, pages 42383 - 42390, XP055406162 (B1)
SUNIL S. JAMBHEKAR ET AL: "Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex", DRUG DISCOVERY TODAY, vol. 21, no. 2, 1 February 2016 (2016-02-01), pages 356-362, XP055497919, AMSTERDAM, NL ISSN: 1359-6446, DOI: 10.1016/j.drudis.2015.11.017 (B1)
THOMAS WIMMER: "Cyclodextrins", ULLMANN'S ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY,, 15 January 2003 (2003-01-15), pages 1-9, XP002509200, DOI: 10.1002/14356007.E08-E02 [retrieved on 2008-12-18] (B1)
Tetsumi Irie ET AL: "Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation", Journal of pharmaceutical sciences, 1 February 1997 (1997-02-01), pages 147-162, XP055749282, New York DOI: 10.1021/js960213f Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
US-A- 4 228 160 (B1)
US-A- 5 134 127 (B1)
US-A- 5 646 131 (B1)
US-A1- 2004 235 125 (B1)
US-A1- 2008 161 288 (B1)
US-A1- 2010 069 536 (B1)
A.J. Cowieson: "Exogenous Microbial Amylase in the Diets of Poultry: What do we know?", J. Appl. Poult. Res., 1 January 2019 (2019-01-01), XP055749271, Retrieved from the Internet: URL:submitted by Applicant [retrieved on 2020-11-11] (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3411047)
|
Utgående
EP Registreringsbrev (3210) (PTEP3411047)
|
Innkommende, AR436609482
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 9. avg. år (EP) | 2025.02.12 | 3710 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2024.02.08 | 2550 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 7. avg. år (EP) | 2023.02.08 | 2200 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 6. avg. år (EP) | 2022.02.08 | 2000 | CPA GLOBAL LIMITED | Betalt og godkjent |
32110170 expand_more expand_less | 2021.06.30 | 5580 | Cosmovici Intellectual Property | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
Gebyr ved bruk av MasterCard-kort
80 = 80 X 1
|